A new injection called lenacapavir has shown 96% effectiveness in preventing HIV infections, surpassing daily oral pills. It is already available under the brand name Sunlenca for treating HIV. The drugmaker Gilead plans to allow generic versions in 120 poor countries but has excluded Latin America, raising concerns about access. UNAIDS reports a significant drop in AIDS deaths, suggesting a historic opportunity to end the epidemic. Advocacy groups are pushing for broader access to the drug in Latin America. Teljes cikk (Euronews.com)